Home
/
ALNYLAM PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
ALNYLAM PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ALNYLAM PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2022
$264.31M
Oct 27, 2022
Q2
2022
Jun 30, 2022
$224.82M
Jul 28, 2022
Q1
2022
Mar 31, 2022
$213.26M
Apr 28, 2022
Q3
2022
Sep 30, 2021
$187.63M
Oct 27, 2022
Q2
2022
Jun 30, 2021
$220.55M
Jul 28, 2022
Q1
2022
Mar 31, 2021
$177.57M
Apr 28, 2022
Q3
2021
Sep 30, 2020
$125.85M
Oct 28, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.25B
Oct 30, 2025
Q2
2025
Jun 30, 2025
$773.69M
Jul 31, 2025
Q1
2025
Mar 31, 2025
$594.19M
May 1, 2025
Q3
2025
Sep 30, 2024
$500.92M
Oct 30, 2025
Q2
2025
Jun 30, 2024
$659.83M
Jul 31, 2025
Q1
2025
Mar 31, 2024
$494.33M
May 1, 2025
Q3
2024
Sep 30, 2023
$750.53M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$318.75M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$319.29M
May 2, 2024
Q3
2023
Sep 30, 2022
$264.31M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$224.82M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$213.26M
May 4, 2023
Q2
2021
Jun 30, 2021
$220.55M
Aug 3, 2021
Q1
2021
Mar 31, 2021
$177.57M
Apr 29, 2021
Q3
2020
Sep 30, 2020
$125.85M
Nov 5, 2020
Q2
2021
Jun 30, 2020
$103.96M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$99.48M
Apr 29, 2021
Q3
2020
Sep 30, 2019
$70.06M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$44.71M
Aug 6, 2020
Q1
2020
Mar 31, 2019
$33.29M
May 6, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2011
Mar 31, 2011
$20.90M
May 5, 2011
Q3
2010
Sep 30, 2010
$27.67M
Nov 4, 2010
Q2
2010
Jun 30, 2010
$26.62M
Aug 5, 2010
Q1
2011
Mar 31, 2010
$24.56M
May 5, 2011
Q3
2010
Sep 30, 2009
$24.25M
Nov 4, 2010
Q2
2010
Jun 30, 2009
$24.60M
Aug 5, 2010
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$251.08M
Oct 30, 2025
Q3
2025
Jun 30, 2025
($66.28M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($66.28M)
Jul 31, 2025
Q2
2025
Mar 31, 2025
($57.48M)
Jul 31, 2025
Q3
2025
Mar 31, 2025
($57.48M)
Oct 30, 2025
Q1
2025
Mar 31, 2025
($57.48M)
May 1, 2025
Q3
2025
Sep 30, 2024
($111.57M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($16.89M)
Jul 31, 2025
Q3
2025
Jun 30, 2024
($16.89M)
Oct 30, 2025
Q3
2025
Mar 31, 2024
($65.94M)
Oct 30, 2025
Q1
2025
Mar 31, 2024
($65.94M)
May 1, 2025
Q2
2025
Mar 31, 2024
($65.94M)
Jul 31, 2025
Q3
2024
Sep 30, 2023
$147.75M
Oct 31, 2024
Q2
2024
Jun 30, 2023
($276.02M)
Aug 1, 2024
Q3
2024
Jun 30, 2023
($276.02M)
Oct 31, 2024
Q1
2024
Mar 31, 2023
($174.10M)
May 2, 2024
Q3
2024
Mar 31, 2023
($174.10M)
Oct 31, 2024
Q2
2024
Mar 31, 2023
($174.10M)
Aug 1, 2024
Q3
2023
Sep 30, 2022
($405.92M)
Nov 2, 2023
Q3
2023
Jun 30, 2022
($277.40M)
Nov 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$367.98M
Oct 30, 2025
Q2
2025
Jun 30, 2025
($16.20M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
$18.08M
May 1, 2025
Q3
2025
Sep 30, 2024
($76.91M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
$48.61M
Jul 31, 2025
Q1
2025
Mar 31, 2024
($43.44M)
May 1, 2025
Q3
2024
Sep 30, 2023
$213.87M
Oct 31, 2024
Q2
2024
Jun 30, 2023
($229.83M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($149.81M)
May 2, 2024
Q3
2023
Sep 30, 2022
($258.04M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($191.69M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($146.73M)
May 4, 2023
Q3
2022
Sep 30, 2021
($181.68M)
Oct 27, 2022
Q2
2022
Jun 30, 2021
($146.16M)
Jul 28, 2022
Q1
2022
Mar 31, 2021
($186.25M)
Apr 28, 2022
Q3
2021
Sep 30, 2020
($225.20M)
Oct 28, 2021
Q2
2021
Jun 30, 2020
($198.86M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
($210.16M)
Apr 29, 2021
Q3
2020
Sep 30, 2019
($216.30M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($236.27M)
Aug 6, 2020